table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2030)
1.4.2 East Asia Market States and Outlook (2023-2030)
1.4.3 Europe Market States and Outlook (2023-2030)
1.4.4 South Asia Market States and Outlook (2023-2030)
1.4.5 Southeast Asia Market States and Outlook (2023-2030)
1.4.6 Middle East Market States and Outlook (2023-2030)
1.4.7 Africa Market States and Outlook (2023-2030)
1.4.8 Oceania Market States and Outlook (2023-2030)
1.4.9 South America Market States and Outlook (2023-2030)
1.5 Global RNA-Based Therapeutics and Vaccines Market Size Analysis from 2023 to 2030
1.5.1 Global RNA-Based Therapeutics and Vaccines Market Size Analysis from 2023 to 2030 by Consumption Volume
1.5.2 Global RNA-Based Therapeutics and Vaccines Market Size Analysis from 2023 to 2030 by Value
1.5.3 Global RNA-Based Therapeutics and Vaccines Price Trends Analysis from 2023 to 2030
1.6 COVID-19 Outbreak: RNA-Based Therapeutics and Vaccines Industry Impact
Chapter 2 Global RNA-Based Therapeutics and Vaccines Competition by Types, Applications, and Top Regions and Countries
2.1 Global RNA-Based Therapeutics and Vaccines (Volume and Value) by Type
2.1.1 Global RNA-Based Therapeutics and Vaccines Consumption and Market Share by Type (2017-2022)
2.1.2 Global RNA-Based Therapeutics and Vaccines Revenue and Market Share by Type (2017-2022)
2.2 Global RNA-Based Therapeutics and Vaccines (Volume and Value) by Application
2.2.1 Global RNA-Based Therapeutics and Vaccines Consumption and Market Share by Application (2017-2022)
2.2.2 Global RNA-Based Therapeutics and Vaccines Revenue and Market Share by Application (2017-2022)
2.3 Global RNA-Based Therapeutics and Vaccines (Volume and Value) by Regions
2.3.1 Global RNA-Based Therapeutics and Vaccines Consumption and Market Share by Regions (2017-2022)
2.3.2 Global RNA-Based Therapeutics and Vaccines Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global RNA-Based Therapeutics and Vaccines Consumption by Regions (2017-2022)
4.2 North America RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.4 Europe RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.8 Africa RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
4.10 South America RNA-Based Therapeutics and Vaccines Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America RNA-Based Therapeutics and Vaccines Market Analysis
5.1 North America RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
5.1.1 North America RNA-Based Therapeutics and Vaccines Market Under COVID-19
5.2 North America RNA-Based Therapeutics and Vaccines Consumption Volume by Types
5.3 North America RNA-Based Therapeutics and Vaccines Consumption Structure by Application
5.4 North America RNA-Based Therapeutics and Vaccines Consumption by Top Countries
5.4.1 United States RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
5.4.2 Canada RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
5.4.3 Mexico RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 6 East Asia RNA-Based Therapeutics and Vaccines Market Analysis
6.1 East Asia RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
6.1.1 East Asia RNA-Based Therapeutics and Vaccines Market Under COVID-19
6.2 East Asia RNA-Based Therapeutics and Vaccines Consumption Volume by Types
6.3 East Asia RNA-Based Therapeutics and Vaccines Consumption Structure by Application
6.4 East Asia RNA-Based Therapeutics and Vaccines Consumption by Top Countries
6.4.1 China RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
6.4.2 Japan RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
6.4.3 South Korea RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 7 Europe RNA-Based Therapeutics and Vaccines Market Analysis
7.1 Europe RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
7.1.1 Europe RNA-Based Therapeutics and Vaccines Market Under COVID-19
7.2 Europe RNA-Based Therapeutics and Vaccines Consumption Volume by Types
7.3 Europe RNA-Based Therapeutics and Vaccines Consumption Structure by Application
7.4 Europe RNA-Based Therapeutics and Vaccines Consumption by Top Countries
7.4.1 Germany RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.2 UK RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.3 France RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.4 Italy RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.5 Russia RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.6 Spain RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.7 Netherlands RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.8 Switzerland RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
7.4.9 Poland RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 8 South Asia RNA-Based Therapeutics and Vaccines Market Analysis
8.1 South Asia RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
8.1.1 South Asia RNA-Based Therapeutics and Vaccines Market Under COVID-19
8.2 South Asia RNA-Based Therapeutics and Vaccines Consumption Volume by Types
8.3 South Asia RNA-Based Therapeutics and Vaccines Consumption Structure by Application
8.4 South Asia RNA-Based Therapeutics and Vaccines Consumption by Top Countries
8.4.1 India RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
8.4.2 Pakistan RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
8.4.3 Bangladesh RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia RNA-Based Therapeutics and Vaccines Market Analysis
9.1 Southeast Asia RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
9.1.1 Southeast Asia RNA-Based Therapeutics and Vaccines Market Under COVID-19
9.2 Southeast Asia RNA-Based Therapeutics and Vaccines Consumption Volume by Types
9.3 Southeast Asia RNA-Based Therapeutics and Vaccines Consumption Structure by Application
9.4 Southeast Asia RNA-Based Therapeutics and Vaccines Consumption by Top Countries
9.4.1 Indonesia RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
9.4.2 Thailand RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
9.4.3 Singapore RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
9.4.4 Malaysia RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
9.4.5 Philippines RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
9.4.6 Vietnam RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
9.4.7 Myanmar RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 10 Middle East RNA-Based Therapeutics and Vaccines Market Analysis
10.1 Middle East RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
10.1.1 Middle East RNA-Based Therapeutics and Vaccines Market Under COVID-19
10.2 Middle East RNA-Based Therapeutics and Vaccines Consumption Volume by Types
10.3 Middle East RNA-Based Therapeutics and Vaccines Consumption Structure by Application
10.4 Middle East RNA-Based Therapeutics and Vaccines Consumption by Top Countries
10.4.1 Turkey RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.3 Iran RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.5 Israel RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.6 Iraq RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.7 Qatar RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.8 Kuwait RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
10.4.9 Oman RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 11 Africa RNA-Based Therapeutics and Vaccines Market Analysis
11.1 Africa RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
11.1.1 Africa RNA-Based Therapeutics and Vaccines Market Under COVID-19
11.2 Africa RNA-Based Therapeutics and Vaccines Consumption Volume by Types
11.3 Africa RNA-Based Therapeutics and Vaccines Consumption Structure by Application
11.4 Africa RNA-Based Therapeutics and Vaccines Consumption by Top Countries
11.4.1 Nigeria RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
11.4.2 South Africa RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
11.4.3 Egypt RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
11.4.4 Algeria RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
11.4.5 Morocco RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 12 Oceania RNA-Based Therapeutics and Vaccines Market Analysis
12.1 Oceania RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
12.2 Oceania RNA-Based Therapeutics and Vaccines Consumption Volume by Types
12.3 Oceania RNA-Based Therapeutics and Vaccines Consumption Structure by Application
12.4 Oceania RNA-Based Therapeutics and Vaccines Consumption by Top Countries
12.4.1 Australia RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
12.4.2 New Zealand RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 13 South America RNA-Based Therapeutics and Vaccines Market Analysis
13.1 South America RNA-Based Therapeutics and Vaccines Consumption and Value Analysis
13.1.1 South America RNA-Based Therapeutics and Vaccines Market Under COVID-19
13.2 South America RNA-Based Therapeutics and Vaccines Consumption Volume by Types
13.3 South America RNA-Based Therapeutics and Vaccines Consumption Structure by Application
13.4 South America RNA-Based Therapeutics and Vaccines Consumption Volume by Major Countries
13.4.1 Brazil RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.2 Argentina RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.3 Columbia RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.4 Chile RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.5 Venezuela RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.6 Peru RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
13.4.8 Ecuador RNA-Based Therapeutics and Vaccines Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in RNA-Based Therapeutics and Vaccines Business
14.1 Alnylam Pharmaceuticals
14.1.1 Alnylam Pharmaceuticals Company Profile
14.1.2 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Specification
14.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Arbutus Biopharma
14.2.1 Arbutus Biopharma Company Profile
14.2.2 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Specification
14.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Arrowhead Pharmaceuticals
14.3.1 Arrowhead Pharmaceuticals Company Profile
14.3.2 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Specification
14.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 BioNTech
14.4.1 BioNTech Company Profile
14.4.2 BioNTech RNA-Based Therapeutics and Vaccines Product Specification
14.4.3 BioNTech RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 CureVac
14.5.1 CureVac Company Profile
14.5.2 CureVac RNA-Based Therapeutics and Vaccines Product Specification
14.5.3 CureVac RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Dicerna Pharmaceuticals
14.6.1 Dicerna Pharmaceuticals Company Profile
14.6.2 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Specification
14.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Regulus Therapeutics
14.7.1 Regulus Therapeutics Company Profile
14.7.2 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Specification
14.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Marina Biotech
14.8.1 Marina Biotech Company Profile
14.8.2 Marina Biotech RNA-Based Therapeutics and Vaccines Product Specification
14.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 MiRagen Therapeutics
14.9.1 MiRagen Therapeutics Company Profile
14.9.2 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Specification
14.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Moderna Therapeutics
14.10.1 Moderna Therapeutics Company Profile
14.10.2 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Specification
14.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 Quark Pharmaceuticals
14.11.1 Quark Pharmaceuticals Company Profile
14.11.2 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Specification
14.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 Roche
14.12.1 Roche Company Profile
14.12.2 Roche RNA-Based Therapeutics and Vaccines Product Specification
14.12.3 Roche RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.13 Sylentis
14.13.1 Sylentis Company Profile
14.13.2 Sylentis RNA-Based Therapeutics and Vaccines Product Specification
14.13.3 Sylentis RNA-Based Therapeutics and Vaccines Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global RNA-Based Therapeutics and Vaccines Market Forecast (2023-2030)
15.1 Global RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Price Forecast (2023-2030)
15.1.1 Global RNA-Based Therapeutics and Vaccines Consumption Volume and Growth Rate Forecast (2023-2030)
15.1.2 Global RNA-Based Therapeutics and Vaccines Value and Growth Rate Forecast (2023-2030)
15.2 Global RNA-Based Therapeutics and Vaccines Consumption Volume, Value and Growth Rate Forecast by Region (2023-2030)
15.2.1 Global RNA-Based Therapeutics and Vaccines Consumption Volume and Growth Rate Forecast by Regions (2023-2030)
15.2.2 Global RNA-Based Therapeutics and Vaccines Value and Growth Rate Forecast by Regions (2023-2030)
15.2.3 North America RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.4 East Asia RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.5 Europe RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.6 South Asia RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.7 Southeast Asia RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.8 Middle East RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.9 Africa RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.10 Oceania RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.11 South America RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.3 Global RNA-Based Therapeutics and Vaccines Consumption Volume, Revenue and Price Forecast by Type (2023-2030)
15.3.1 Global RNA-Based Therapeutics and Vaccines Consumption Forecast by Type (2023-2030)
15.3.2 Global RNA-Based Therapeutics and Vaccines Revenue Forecast by Type (2023-2030)
15.3.3 Global RNA-Based Therapeutics and Vaccines Price Forecast by Type (2023-2030)
15.4 Global RNA-Based Therapeutics and Vaccines Consumption Volume Forecast by Application (2023-2030)
15.5 RNA-Based Therapeutics and Vaccines Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
